Furthermore, while both the AKT and ERK1/2 pathways can be activated by inflammatory cytokines, MED12 KO NSCLC cell lines specifically exhibit activation of the ERK1/2 pathway, highlighting a unique and distinct mechanism of RTKi resistance. The gene discussed is MAPK3; the disease is non-small cell lung carcinoma.